info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A short-term clinical framework that reduces acute inflammatory signaling, controls pain, and speeds early tissue repair after injury or procedures.
A structured, short-term clinical framework to reduce acute inflammatory signaling, control pain amplification, and speed early tissue repair after injury or procedural inflammation. The protocol combines local tissue-support peptides with systemic anti-inflammatory modulators and, when indicated, mitochondrial support to keep inflammation from becoming chronic.
The goal is to move patients efficiently from the acute inflammatory phase into functional recovery, with defined cycling and monitoring parameters.
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | Subcutaneous (SubQ), perilesional | 250–500 mcg | Twice daily | 4–6 weeks |
| KPV | SubQ or oral | 200–500 mcg | 1–2 times daily | 4–6 weeks |
| Selank | Intranasal | 200–400 mcg | Twice daily | 2–4 weeks |
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| TB-500 (thymosin β4) | SubQ | 750 mcg–1.5 mg | Twice weekly (Weeks 1–2), then weekly | 6–8 weeks |
| SS-31 (elamipretide) | SubQ | 0.5–1.0 mg | Daily | 4 weeks |
This protocol combines localized angiogenic signaling with systemic inflammatory modulation. BPC-157 is the anchor peptide for tissue repair and nitric oxide support. KPV directly modulates the NF-κB pathway. Selank reduces central sensitization and anxiety-amplified pain signaling.
When required, TB-500 enhances cellular migration, and SS-31 stabilizes mitochondrial membranes to limit the spread of oxidative stress.
